Chronic Pain
The most evidence-supported indication for medical cannabis
Chronic pain — particularly neuropathic pain — has the strongest evidence base for cannabinoid therapy. Multiple RCTs and meta-analyses support modest but meaningful pain reduction, especially when conventional treatments have failed.
At a Glance
Overview
Chronic pain affects an estimated 50 million adults in the U.S. and is the most common reason patients seek medical cannabis. It encompasses neuropathic pain (nerve damage), nociceptive pain (tissue damage), and mixed pain syndromes.
The endocannabinoid system plays a direct role in pain modulation. CB1 receptors are densely expressed in pain-processing regions of the brain and spinal cord, while CB2 receptors modulate peripheral and neuroinflammatory pain. Both THC and CBD interact with these pathways, though through different mechanisms.
A landmark 2018 Cochrane review of 47 RCTs (n=4,743) found moderate-quality evidence that cannabis-based medicines produce clinically meaningful pain reduction (≥30% reduction) in chronic neuropathic pain, with a number needed to treat (NNT) of approximately 11. A 2022 JAMA Network Open meta-analysis of 32 trials found cannabis-based medicines significantly reduced pain intensity (SMD −0.50) versus placebo.
The evidence is strongest for neuropathic pain (diabetic neuropathy, HIV-associated neuropathy, central sensitization) and weakest for musculoskeletal pain. THC-containing preparations consistently outperform CBD-only products for pain, though the combination (as in nabiximols/Sativex) is preferred clinically due to CBD's attenuation of THC's psychoactive effects.
Cannabis is generally considered an adjunctive therapy for pain — used alongside, not instead of, conventional analgesics. An important emerging area is the opioid-sparing effect: several observational studies suggest patients using cannabis reduce opioid doses by 30–64%, though RCT evidence for this is limited.
Symptoms
- Persistent pain >3 months
- Burning or shooting sensations (neuropathic)
- Hyperalgesia
- Allodynia
- Sleep disruption
- Functional impairment
- Depression and anxiety comorbidity
How Cannabis Helps
THC activates CB1 receptors in pain-processing pathways, reducing pain signal transmission. CBD modulates TRPV1 channels and reduces neuroinflammation. Together they produce synergistic analgesia with reduced psychoactivity compared to THC alone.
Treatment Options
Graded by quality of evidence. Grade A = strong (RCTs/FDA approval); B = moderate; C = preliminary.
THC + CBD (nabiximols)
Oromucosal spray
Most studied combination. Approved in 30+ countries for neuropathic pain and MS spasticity.
Sativex (1:1 THC:CBD) — not FDA-approved but available in Canada and Europe
THC (dronabinol)
Oral capsule
FDA-approved for CINV; used off-label for pain. Slower onset than inhaled.
CBD
Oral tincture / capsule
Modest analgesic effects alone. More effective combined with THC. Useful for patients who cannot tolerate THC psychoactivity.
Inhaled cannabis (THC-dominant)
Vaporized flower or concentrate
Rapid onset (5–10 min). Multiple small RCTs show significant pain reduction. Dose control is challenging.
Vaporization preferred over combustion to reduce respiratory risks
Key Studies
Primary literature supporting the evidence grade for this indication.
Cannabis-based medicines for chronic neuropathic pain in adults
Grade ACochrane Database of Systematic Reviews, 2018
47 RCTs, n=4,743. Moderate evidence for ≥30% pain reduction. NNT ≈ 11.
Efficacy and Safety of Medical Cannabis for Chronic Noncancer Pain
Grade AJAMA Network Open, 2022
32 trials. Cannabis significantly reduced pain intensity (SMD −0.50) vs. placebo.
Smoked cannabis for chronic neuropathic pain
Grade BCMAJ, 2010
Crossover RCT. 9.4% THC cannabis significantly reduced pain vs. placebo.
Side Effects to Watch
- Dizziness and sedation (especially at initiation)
- Cognitive impairment with high-THC products
- Anxiety or paranoia (dose-dependent)
- Tolerance development with chronic use
- Cannabis use disorder risk (~9% of users)
Who Should Avoid
- Personal or family history of psychosis or schizophrenia
- Pregnancy or breastfeeding
- Adolescents and young adults (<25)
- Severe cardiovascular disease
- Current substance use disorder
Dosing Guidance
Start with low-THC or CBD-dominant products. Titrate slowly over weeks. For inhaled: 1–2 puffs, wait 15 minutes before re-dosing. For oral: 2.5–5 mg THC starting dose, increase by 2.5 mg every 3–7 days. Target the lowest effective dose.
Dosing information is for educational purposes only. Consult a licensed healthcare provider for personalized guidance.
Clinician Note
Cannabis is best positioned as a third-line adjunctive analgesic after conventional therapies. Screen for contraindications (psychosis history, pregnancy, age <25). Monitor for CUD development. The opioid-sparing potential is clinically relevant but requires more RCT evidence.
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Cannabis remains a Schedule I controlled substance federally in the U.S. Always consult a qualified healthcare provider before making any medical decisions. Individual responses to cannabinoids vary significantly.